Ionis Pharmaceuticals, Inc.
RNA-targeted medicines company whose antisense platform discovered diranersen (IONIS-MAPTRx / BIIB080), a MAPT-directed antisense oligonucleotide for Alzheimer's disease; Biogen exercised its licence option and holds a worldwide exclusive royalty-bearing licence to develop and commercialise it.
Longevity thesis
Antisense discovery against a defined mRNA target lets one platform address age-associated proteinopathies it does not itself take through late clinical development.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| Diranersen (discovered by Ionis; licensed to Biogen) | Not curated | Alzheimer's disease |
Recent developments
- 14 May 2026Company stated it discovered diranersen and that Biogen exercised its licence option, obtaining a worldwide exclusive royalty-bearing licence to develop and commercialise diranersen.
Scientific evidence
Company-reported only. LONGEFI holds no independent Evidence Record. Ionis' representation records discovery origin and licensing, not clinical control or outcome.
LONGEFI analysis
Curated deliberately narrowly: only the diranersen origin relationship relevant to LONGEFI's read-through surface, not the wider Ionis pipeline.
Analysis is research commentary. It is not investment advice or a recommendation.